Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium adolescentis has been investigated for its potential to alleviate some side effects of chemotherapy, mainly by supporting gut health and modulating immune responses. Chemotherapy often disrupts the intestinal microbiota, leading to gastrointestinal symptoms such as diarrhea, mucositis, and increased susceptibility to infections. Several preclinical and a few early clinical studies suggest that B. adolescentis, as part of a probiotic regimen, may help restore the balance of gut microbiota, enhance the intestinal barrier, and reduce inflammation.

Animal studies have shown that supplementation with B. adolescentis can reduce chemotherapy-induced mucosal injury and decrease inflammatory cytokines. Some small clinical trials and case reports have included B. adolescentis in multi-strain probiotic formulations, showing reduced severity of diarrhea and improved gut function in patients undergoing chemotherapy. However, these studies often combine multiple probiotic strains, making it difficult to isolate the specific effects of B. adolescentis. Additionally, larger and more rigorous clinical trials are needed to confirm efficacy and establish safety in this context.

Overall, there is a growing body of preclinical and early clinical evidence supporting the use of B. adolescentis to mitigate chemotherapy side effects, but the current evidence base is still limited and not definitive. The rating reflects the preliminary but promising nature of the research.

More about Bifidobacterium adolescentis
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Bifidobacterium adolescentis

Products containing Bifidobacterium adolescentis